60 Degrees Pharmaceuticals’ Tafenoquine Gains the US FDA’s Orphan Drug Designation to Treat Acute Babesiosis
Shots:
- The US FDA has granted orphan drug designation to the company’s tafenoquine as a treatment for acute babesiosis
- Tafenoquine is being investigated under the P-II study for its safety and efficacy vs PBO for the treatment of acute babesiosis hospitalized patients (n=24) who are at less risk of relapsing; patients will also receive SoC antimicrobial regimen
- Furthermore, the company has collaborated with Tufts Medical Center to carry out the clinical evaluation, the enrollment for which will be initiated on June 13, 2024, with additional recruitment sites at prominent university hospitals across the Northeast US
Ref: 60 Degrees Pharmaceuticals | Image: 60 Degrees Pharmaceuticals
Related News:- 60 Degree Pharma Receives U.S. FDA Approval for ARAKODA (tafenoquine) tablets for Treating Malaria
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
